Cassaday & Co Wealth Management’s AbbVie ABBV Stock Holding History

Cassaday & Co Wealth Management’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$4.5M	Sell	20,675 -60	-0.3%	-$13.3K	0.1%	46
2025 Q4	$4.74M	Sell	20,735 -211	-1%	-$48.1K	0.1%	46
2025 Q3	$4.85M	Buy	20,946 +212	+1%	+$43.2K	0.11%	47
2025 Q2	$3.85M	Buy	20,734 +144	+0.7%	+$26.8K	0.1%	52
2025 Q1	$4.31M	Sell	20,590 -252	-1%	-$49K	0.12%	42
2024 Q4	$3.7M	Buy	20,842 +75	+0.4%	+$13.8K	0.1%	46
2024 Q3	$4.1M	Sell	20,767 -208	-1%	-$38.8K	0.12%	40
2024 Q2	$3.6M	Sell	20,975 -98	-0.5%	-$16.2K	0.11%	43
2024 Q1	$3.84M	Buy	21,073 +469	+2%	+$80.8K	0.12%	42
2023 Q4	$3.19M	Sell	20,604 -272	-1%	-$39.7K	0.11%	43
2023 Q3	$3.11M	Sell	20,876 -179	-0.9%	-$26.3K	0.13%	39
2023 Q2	$2.84M	Sell	21,055 -85	-0.4%	-$12.5K	0.11%	41
2023 Q1	$3.37M	Sell	21,140 -341	-2%	-$52.1K	0.14%	36
2022 Q4	$3.47M	Buy	+21,481	New	+$3.29M	0.16%	36

Other funds holding ABBV

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Cassaday & Co Wealth Management's ABBV Position: Q1 2026 in Review

Cassaday & Co Wealth Management reduced its AbbVie (ABBV) stake by 0.29% in Q1 2026, selling an estimated $13.3K and leaving 20,675 shares worth $4.5M. The position accounts for 0.1% of the portfolio, ranked #46.

Cassaday & Co Wealth Management first reported a position in ABBV in Q4 2022 and has held it in 14 quarters since. The position peaked at $4.85M in Q3 2025. 4,076 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.

Cassaday & Co Wealth Management held 20,675 shares of AbbVie worth $4.5M as of Q1 2026.
Cassaday & Co Wealth Management sold 60 AbbVie shares in Q1 2026, an estimated $13.3K.
AbbVie made up 0.1% of Cassaday & Co Wealth Management's portfolio in Q1 2026, its #46 holding.
Cassaday & Co Wealth Management first reported a position in AbbVie in Q4 2022 and has held it in 14 quarters since.
Cassaday & Co Wealth Management's AbbVie position peaked at $4.85M in Q3 2025.
4,076 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.

Based on Cassaday & Co Wealth Management's 13F filing for Q1 2026, filed 7 May 2026.